- Home
- About
- Find staff
- Tom Bäck
Tom Bäck
Researcher
Department of Medical RadiationAbout Tom Bäck
Research areas: Targeted radionuclide therapy of cancer using alpha-particle emitters. Small-scale dosimetry, Radiobiology, Alpha-particle imaging, therapeutics and pharmacokinetics, renal toxicity, animal models.
-
A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells In
Vitro
Tom Bäck, Per Albertsson, Emma Aneheim, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren, Stig Palm
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS - 2024 -
Astatine-211 based radionuclide therapy: Current clinical trial
landscape
Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, K. Smerud, Stig Palm
Frontiers in Medicine - 2023 -
Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and
Astatine-211
Chiara Timperanza, H. Jensen, Tom Bäck, Sture Lindegren, Emma Aneheim
Pharmaceuticals - 2023 -
Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal
radioimmunotherapy.
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, Per Albertsson
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2022 -
Covalent core-radiolabeling of polymeric micelles with125I/211At for theranostic
radiotherapy
E. Sporer, C. B. M. Poulie, Tom Bäck, Sture Lindegren, H. Jensen, P. J. Kempen, A. Kjaer, M. M. Herth, A. I. Jensen
Nanotheranostics - 2022 -
Radium-223-Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone
Marrow
B. S. Canter, C. N. Leung, J. C. Fritton, Tom Bäck, D. Rajon, E. I. Azzam, R. W. Howell
Molecular Cancer Research - 2021 -
Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian
cancer
Stig Palm, Tom Bäck, Emma Aneheim, Andreas Hallqvist, Ragnar Hultborn, Lars Jacobsson, H. Jensen, Sture Lindegren, Per Albertsson
Translational Oncology - 2021 -
Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with
radium-223
D. A. Rajon, B. S. Canter, C. N. Leung, Tom Bäck, J. C. Fritton, E. I. Azzam, R. W. Howell
International Journal of Radiation Biology - 2021 -
Realizing Clinical Trials with Astatine-211: The Chemistry
Infrastructure
Sture Lindegren, Per Albertsson, Tom Bäck, H. Jensen, Stig Palm, Emma Aneheim
Cancer Biotherapy and Radiopharmaceuticals - 2020 -
Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with Ra-223: The Role of Bystander Effects and Their Potential for
Therapy
C. N. Leung, B. S. Canter, D. Rajon, Tom Bäck, J. C. Fritton, E. I. Azzam, R. W. Howell
Journal of Nuclear Medicine - 2020 -
Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone
microtumors
Tom Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, H. Jensen, T. Olafsen, P. J. Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, A. M. Wu, Karin Welén
Ejnmmi Research - 2020 -
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo
Behavior
Y. Dekempeneer, Tom Bäck, Emma Aneheim, H. Jensen, J. Puttemans, C. Xavier, M. Keyaerts, Stig Palm, Per Albertsson, T. Lahoutte, V. Caveliers, Sture Lindegren, M. D'Huyvetter
Molecular Pharmaceutics - 2019 -
Intraperitoneal alpha-Emitting Radioimmunotherapy with At-211 in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose
Estimations
Andreas Hallqvist, Karin Bergmark, Tom Bäck, Håkan Andersson, Pernilla Dahm-Kähler, Mia Johansson, Sture Lindegren, H. Jensen, Lars Jacobsson, Ragnar Hultborn, Stig Palm, Per Albertsson
Journal of Nuclear Medicine - 2019 -
Astatine-211: The Chemistry
Infrastructure.
Sture Lindegren, Tom Bäck, Stig Palm, Holger Jensen, Per Albertsson, Emma Aneheim
Journal of Medical Imaging and Radiation Sciences - 2019 -
Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose
Estimations.
Andreas Hallqvist, Per Albertsson, Ragnar Hultborn, Stig Palm, Karin Bergmark, Tom Bäck, Håkan Andersson, Pernilla Dahm-Kähler, Mia Johansson, Sture Lindegren, Holger Jensen, Lars Jacobsson
Journal of Medical Imaging and Radiation Sciences - 2019 -
Estimation of Long-term Risks for Cancer Induction following Adjuvant Targeted Alpha Therapy with Curative
Intent.
Stig Palm, Andreas Hallqvist, Emma Aneheim, Tom Bäck, Mia Johansson, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren, Per Albertsson
Journal of Medical Imaging and Radiation Sciences - 2019 -
Quantified Cell Binding of Astatinated Immunoconjugates onOvarian Cancer Cell Spheroids by Alpha Camera
Imaging.
Tom Bäck, M Verhoeven, Emma Aneheim, Per Albertsson, Stig Palm, Sture Lindegren, Holger Jensen
Journal of Medical Imaging and Radiation Sciences - 2019 -
Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor
Sizes.
Stig Palm, Tom Bäck, Sture Lindegren, Ragnar Hultborn, Lars Jacobsson, Per Albertsson
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2018 -
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen,
NaPi2b
Kristina Levan, Martin Mehryar, Constantina Mateoiu, Per Albertsson, Tom Bäck, Karin Sundfeldt
Bmc Cancer - 2017 -
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer
model
J. R. Nedrow, A. Josefsson, S. Park, Tom Bäck, R. F. Hobbs, C. Brayton, F. Bruchertseifer, A. Morgenstern, G. Sgouros
Ejnmmi Research - 2017 -
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated alpha-Radioimmunotherapy with At-211-MX35-F(ab')(2): Influence of Absorbed Tumor Dose and Effect on Long-Term
Survival
Tom Bäck, N. Chouin, Sture Lindegren, Helena Kahu, H. Jensen, Per Albertsson, Stig Palm
Journal of Nuclear Medicine - 2017 -
Therapeutic efficacy of alpha-radioimmunotherapy with different activity levels of the Bi-213-labeled monoclonal antibody MX35 in an ovarian cancer
model
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, Ragnar Hultborn, Stig Palm, Lars Jacobsson, A. Morgenstern, F. Bruchertseifer, Per Albertsson, Sture Lindegren
EJNMMI Research - 2017 -
Biokinetic modeling and dosimetry for optimizing intraperitoneal radioimmunotherapy of ovarian cancer
microtumors.
Stig Palm, Tom Bäck, Börje Haraldsson, Lars Jacobsson, Sture Lindegren, Per Albertsson
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2016 -
Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide
Immunoconjugates
Emma Aneheim, Anna Gustafsson, Per Albertsson, Tom Bäck, Holger Jensen, Stig Palm, Sofia Svedhem, Sture Lindegren
Bioconjugate chemistry - 2016 -
MIRD monograph - Radiobiology and dosimetry for radiopharmaceutical therapy with alpha-particle
emitters.
G Sgouros, Stig Palm, Tom Bäck, Barry Allen, A. Bertrand Brill, Darrell R. Fisher, Robert F. Hobbs, Roger W. Howell, Michael R. McDevitt, Ruby F. Meredith, Brian W. Miller, John C. Roeske, Stavroula Sofou, Hong Song, Julien Torgue, Michael R. Zalutsky
2015 -
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell
Transplantation.
Sofia Frost, Brian W Miller, Tom Bäck, Erlinda B Santos, Donald K Hamlin, Sue E Knoblaugh, Shani L Frayo, Aimee L Kenoyer, Rainer Storb, Oliver W Press, D Scott Wilbur, John M Pagel, Brenda M Sandmaier
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2015 -
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version
Rebmab200.
Sture Lindegren, Luciana N S Andrade, Tom Bäck, Camila Maria L Machado, Bruno Brasil Horta, Carlos Buchpiguel, Ana Maria Moro, Oswaldo Keith Okamoto, Lars Jacobsson, Elin Cederkrantz, Kohshin Washiyama, Emma Aneheim, Stig Palm, Holger Jensen, Maria Carolina B Tuma, Roger Chammas, Ragnar Hultborn, Per Albertsson
PloS one - 2015 -
Automated astatination of biomolecules--a stepping stone towards multicenter clinical
trials.
Emma Aneheim, Per Albertsson, Tom Bäck, Holger Jensen, Stig Palm, Sture Lindegren
Scientific reports - 2015 -
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse
model.
Damian J Green, Mazyar Shadman, Jon C Jones, Shani L Frayo, Aimee L Kenoyer, Mark D Hylarides, Donald K Hamlin, D Scott Wilbur, Ethan R Balkan, Yukang Lin, Brian W Miller, Sofia Frost, Ajay K Gopal, Johnnie J Orozco, Theodore A Gooley, Kelly L Laird, Brian G Till, Tom Bäck, Brenda M Sandmaier, John M Pagel, Oliver W Press
Blood - 2015 -
Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft
Models.
Sofia Frost, Shani L Frayo, Brian W Miller, Johnnie J Orozco, Garrett C Booth, Mark D Hylarides, Yukang Lin, Damian J Green, Ajay K Gopal, John M Pagel, Tom Bäck, Darrell R Fisher, Oliver W Press
PloS one - 2015 -
Modelling the biokinetics of intra-peritoneally administered targeted alpha therapy on patients for improved
dosimetry.
Stig Palm, Tom Bäck, Sture Lindegren, Holger Jensen, Per Albertsson, Lars Jacobsson
Journal of Nuclear Medicine - 2014 -
Effective dose of intraperitoneal α-radioimmunotherapy with
211At.
Elin Cederkrantz, Tom Bäck, Lars Jacobsson, Holger Jensen, Sture Lindegren, Stig Palm, Per Albertsson
Journal of Nuclear Medicine - 2014 -
Image-based small-scale 3D-dosimetry in targeted alpha therapy using voxel dose-point kernels and alpha camera imaging of serial tissue
sections.
Tom Bäck, Nicolas Chouin, Sture Lindegren, Holger Jensen, Per Albertsson, Stig Palm
Journal of Nuclear Medicine - 2014 -
Polylysine-based Effector Molecules and Clearing Agents for Pretargeting Systems in Therapy and Imaging – Increasing Avidity and Specific Activity and Providing Many Ways to Optimize In Vivo
Distribution.
Anna Gustafsson-Lutz, Tom Bäck, Per Albertsson, Stig Palm, A Morgenstern, F Bruchertseifer, Sture Lindegren
European Journal of Nuclear Medicine and Molecular Imaging - 2014 -
Intra-tumoral dose distributions after experimental targeted alpha therapy by Alpha-Camera
imaging.
Nicolas Chouin, Stig Palm, Sture Lindegren, Holger Jensen, Per Albertsson, Tom Bäck
European Journal of Nuclear Medicine and Molecular Imaging - 2014 -
Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation
status.
Madeleine Nordén Lyckesvärd, Ulla Delle, Helena Kahu, Sture Lindegren, Holger Jensen, Tom Bäck, John Swanpalmer, Kerstin Elmroth
Mutation research. Fundamental and molecular mechanisms of mutagenesis - 2014 -
Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma
Model.
Sophie E Eriksson, Erika Elgström, Tom Bäck, Tomas Ohlsson, Holger Jensen, Rune Nilsson, Sture Lindegren, Jan Tennvall
Cancer biotherapy & radiopharmaceuticals - 2014 -
Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera
Technique.
Nicolas Chouin, Sture Lindegren, Sofia Frost, Holger Jensen, Per Albertsson, Ragnar Hultborn, Stig Palm, Lars Jacobsson, Tom Bäck
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2013 -
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia
model.
Johnnie J Orozco, Tom Bäck, Aimee Kenoyer, Ethan R Balkin, Donald K Hamlin, D Scott Wilbur, Darrell R Fisher, Shani L Frayo, Mark D Hylarides, Damian J Green, Ajay K Gopal, Oliver W Press, John M Pagel
Blood - 2013 -
Comparison of (211)At-PRIT and (211)At-RIT of Ovarian Microtumors in a Nude Mouse
Model.
Sofia Frost, Tom Bäck, Nicolas Chouin, Ragnar Hultborn, Lars Jacobsson, Jörgen Elgqvist, Holger Jensen, Per Albertsson, Sture Lindegren
Cancer biotherapy & radiopharmaceuticals - 2013 -
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with
211At-mAb.
Sophie E Eriksson, Tom Bäck, Erika Elgström, Holger Jensen, Rune Nilsson, Sture Lindegren, Jan Tennvall
EJNMMI research - 2013 -
Tumor Growth of Subcutaneous Xenografts after Repeated Alpha-Radioimmunotherapy with Astatine-211: What Absorbed Dose is Required to Treat Solid Tumors with Alpha-particle
Emitters?
Tom Bäck, Nicolas Chouin, Sture Lindegren, Holger Jensen, Stig Palm, Per Albertsson
European Journal of Nuclear Medicine and Molecular Imaging - 2012 -
Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha
therapy.
Nicolas Chouin, Sture Lindegren, Holger Jensen, Per Albertsson, Tom Bäck
Quarterly Journal of Nuclear Medicine and Molecular Imaging - 2012 -
Comparison of therapeutic efficacy and biodistribution of (213)Bi- and (211)At-labeled monoclonal antibody MX35 in an ovarian cancer
model.
Anna Gustafsson, Tom Bäck, Jörgen Elgqvist, Lars Jacobsson, Ragnar Hultborn, Per Albertsson, Alfred Morgenstern, Frank Bruchertseifer, Holger Jensen, Sture Lindegren
Nuclear medicine and biology - 2012 -
Evaluation of Effects on the Peritoneum After Intraperitoneal α-Radioimmunotherapy with
(211)At.
Elin Cederkrantz, Eva Angenete, Tom Bäck, Peter Falk, Börje Haraldsson, Marie-Louise Ivarsson, Holger Jensen, Sture Lindegren, Ragnar Hultborn, Lars Jacobsson
Cancer biotherapy & radiopharmaceuticals - 2012 -
Statistical and dosimetric analysis of the penetration of antibody fragments F(ab')2 radiolabeled with 211At within subcutaneous
tumors.
Nicolas Chouin, Tom Bäck, M Bardies, Sofia Frost, Sture Lindegren, Stig Palm, O Press, Lars Jacobsson
Journal of Nuclear Medicine - 2011 -
In Vivo Distribution of Avidin-Conjugated MX35 and (211)At-Labeled, Biotinylated Poly-l-Lysine for Pretargeted Intraperitoneal
?-Radioimmunotherapy.
Sofia Frost, Tom Bäck, Nicolas Chouin, Holger Jensen, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren
Cancer biotherapy & radiopharmaceuticals - 2011 -
Alpha-radioimmunotherapy with At-211: Evaluations and imaging on normal tissues and
tumors
Tom Bäck
2011 -
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft
model.
John M Pagel, Aimee L Kenoyer, Tom Bäck, Donald K Hamlin, D Scott Wilbur, Darrell R Fisher, Steven I Park, Shani Frayo, Amanda Axtman, Nural Orgun, Johnnie Orozco, Jaideep Shenoi, Yukang Lin, Ajay K Gopal, Damian J Green, Frederick R Appelbaum, Oliver W Press
Blood - 2011 -
The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of
alpha-particles.
Tom Bäck, Lars Jacobsson
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2010 -
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual
disease
Steven I. Park, Jaideep Shenoi, John M. Pagel, Don K. Hamlin, D. Scott Wilbur, Nural Orgun, Aimee L. Kenoyer, Shani Frayo, Amanda Axtman, Tom Bäck, Yukang Lin, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, Oliver W. Press
BLOOD - 2010 -
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I
study.
Håkan Andersson, Elin Cederkrantz, Tom Bäck, Chaitanya Divgi, Jörgen Elgqvist, Jakob Himmelman, György Horvath, Lars Jacobsson, Holger Jensen, Sture Lindegren, Stig Palm, Ragnar Hultborn
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2009 -
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude
mice.
Tom Bäck, Börje Haraldsson, Ragnar Hultborn, Holger Jensen, Martin E Johansson, Sture Lindegren, Lars Jacobsson
Cancer biotherapy & radiopharmaceuticals - 2009 -
Intraperitoneal alpha-radioimmunotherapy of ovarian cancer – pharmacokinetics and dosimetry of 211At-MX35 F(ab’)2 in a phase I
study.
E Haglund, Håkan Andersson, Tom Bäck, C Divgi, Jörgen Elgqvist, Sofia Frost, Jakob Himmelman, György Horvath, Ragnar Hultborn, Holger Jensen, Sture Lindegren, Stig Palm, Lars Jacobsson
Cancer Biotherapy and Radiopharmaceuticals - 2008 -
Intraperitoneal alpha-radioimmunotherapy of ovarian cancer – pharmacokinetics and dosimetry of 211At-MX35 F(ab’)2 in a phase I
study.
E Haglund, Håkan Andersson, Tom Bäck, C Divgi, Jörgen Elgqvist, Sofia Frost, Jakob Himmelman, György Horvath, Ragnar Hultborn, Holger Jensen, Sture Lindegren, Stig Palm, Lars Jacobsson
Radiotherapy and Oncology - 2008 -
Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide
immunoconjugate.
Sture Lindegren, Sofia Frost, Tom Bäck, Elin Haglund, Jörgen Elgqvist, Holger Jensen
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2008 -
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude
mice.
Stig Palm, Tom Bäck, Ingela Claesson, Anna Danielsson, Jörgen Elgqvist, Sofia Frost, Ragnar Hultborn, Holger Jensen, Sture Lindegren, Lars Jacobsson
International journal of radiation oncology, biology, physics - 2007 -
Biodistribution of free 225Ac in nude
mice.
Stig Palm, Tom Bäck, Jörgen Elgqvist, Ragnar Hultborn, Helena Kahu, Sture Lindegren, Elisabet Warnhammar, Lars Jacobsson
Cancer Biotherapy and Radiopharmaceuticals - 2006 -
Pharmacokinetics and dosimetry of 211At-MX35 F(ab')2 in therapy of ovarian cancer - preliminary results from an ongoing phase I
study.
Ragnar Hultborn, Håkan Andersson, Tom Bäck, C Divgi, Jörgen Elgqvist, Jakob Himmelman, György Horvath, Holger Jensen, Sture Lindegren, Stig Palm, Lars Jacobsson
Cancer Biotherapy and Radiopharmaceuticals - 2006 -
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35
F(ab')2.
Jörgen Elgqvist, Håkan Andersson, Peter Bernhardt, Tom Bäck, Ingela Claesson, Ragnar Hultborn, Holger Jensen, Bengt R Johansson, Sture Lindegren, Marita Olsson, Stig Palm, Elisabet Warnhammar Finnborg, Lars Jacobsson
International journal of radiation oncology, biology, physics - 2006 -
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed
dose.
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, Ingela Claesson, Ragnar Hultborn, Holger Jensen, Bengt R Johansson, Sture Lindegren, Marita Olsson, Stig Palm, Elisabet Warnhammar Finnborg, Lars Jacobsson
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2006 -
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and
myelotoxicity
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, Ingela Claesson, Ragnar Hultborn, H. Jensen, Sture Lindegren, Marita Olsson, Stig Palm, Elisabet Warnhammar Finnborg, Lars Jacobsson
Nucl Med Biol - 2006 -
Alpha-particle emitter [211At] mediated anticancer efficacy of Trastuzumab: Single-dose and fractionated 211At-Herceptin therapy in a nude mouse ovarian carcinoma
model.
Stig Palm, Tom Bäck, Ingela Claesson, Jörgen Elgqvist, Ragnar Hultborn, Börje Karlsson, Sture Lindegren, Lars Jacobsson
Journal of Nuclear Medicine - 2005 -
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody
MX35
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, Ragnar Hultborn, H. Jensen, Börje Karlsson, Sture Lindegren, Stig Palm, Elisabet Warnhammar Finnborg, Lars Jacobsson
J Nucl Med - 2005 -
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in
vivo
Tom Bäck, Håkan Andersson, C. R. Divgi, Ragnar Hultborn, H. Jensen, Sture Lindegren, Stig Palm, Lars Jacobsson
J Nucl Med - 2005 -
Antitumor effect of At-211-radioimmunotherapy on subcutaneous human ovarian cancer xenografts: Evaluation of RBE of an alpha emitter in
vivo.
Tom Bäck, Stig Palm, Sture Lindegren, Börje Karlsson, Ragnar Hultborn, Lars Jacobsson
Cancer Biotherapy and Radiopharmaceuticals - 2004 -
Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and
retention
Stig Palm, Tom Bäck, Ingela Claesson, Ulla Delle, Ragnar Hultborn, Sture Lindegren, Lars Jacobsson
Anticancer Res - 2003 -
At-211 labelled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumour
model.
Ragnar Hultborn, Håkan Andersson, Tom Bäck, Ingela Claesson, Ulla Delle, Jörgen Elgqvist, György Horvath, Lars Jacobsson, Holger Jensen, Sture Lindegren, Stig Palm, Elisabet Warnhammar Finnborg
Cancer Biotherapy and Radiopharmaceuticals - 2002 -
Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor
therapy.
Sture Lindegren, Håkan Andersson, Lars Jacobsson, Tom Bäck, Gunnar Skarnemark, Börje Karlsson
Bioconjugate chemistry - 2002 -
Exploring the anticancer potential of the alpha-particle emitter
astatine-211.
Stig Palm, Håkan Andersson, Tom Bäck, Ingela Claesson, Ulla Delle, György Horvath, Ragnar Hultborn, Lars Jacobsson, Börje Karlsson, Sture Lindegren
Anticancer Research - 2001 -
Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian
cancer.
Håkan Andersson, Stig Palm, Sture Lindegren, Tom Bäck, Lars Jacobsson, Gunilla Leser, György Horvath
Anticancer research - 2001 -
In vitro effects and microdosimetry of 211At for tumour
therapy.
Stig Palm, Håkan Andersson, Tom Bäck, Ingela Claesson, Ulla Delle, Ragnar Hultborn, Lars Jacobsson, Istvan Köpf, Sture Lindegren
International Journal of Radiation Oncology, Biology, Physics - 2000 -
Cell growth kinetics of the human cell line Colo-205 irradiated with photons and astatine-211
alpha-particles
Stig Palm, Håkan Andersson, Tom Bäck, Ingela Claesson, Ulla Delle, Ragnar Hultborn, Lars Jacobsson, Istvan Köpf, Sture Lindegren
Anticancer Res - 2000 -
In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell
lines
Stig Palm, Håkan Andersson, Tom Bäck, Ingela Claesson, Ulla Delle, Ragnar Hultborn, Lars Jacobsson, Istvan Köpf, Sture Lindegren
Anticancer Res - 2000 -
Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth
assay
Stig Palm, Tom Bäck, Ingela Claesson, Ulla Delle, Ragnar Hultborn, Lars Jacobsson, Istvan Köpf, Sture Lindegren
Anticancer Res - 1998